Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
INFU Catalyst Timeline
Dated clinical, regulatory and corporate events for InfuSystem Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for InfuSystem Holdings, Inc.
Event history 5
Past FDA Catalysts and PDUFA Decisions
How INFU actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
InfuSystem Holdings, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every INFU program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Funke JerodOfficer (EVP-Chief HR Officer) | Option | 7,157 36,811 held | $0.00 | 10/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INFU
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 1.1 % (-15.4 %) | 5.23 M | 251.57 K | -9.78% ( -27.27 K) |
Ownership Trends
INFU Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How INFU ranks across every disease it competes in
INFU News
InfuSystem Announces Financial Results for Third Quarter 2026
InfuSystem Holdings reported a 3.0% increase in net revenues for Q3 2026, totaling $37.6 million. Patient Services drove growth with a 15% rise in revenue, while Device Solutions faced a 17% decline. The company reaffirmed its full-year guidance, expecting pro-forma revenue growth of 6% to 8%. Adjusted EBITDA increased by 12%, reflecting strong operational performance.
Read more →InfuSystem Announces Change in Third Quarter 2026 Earnings Release Date
InfuSystem has announced a change in the release date for its third quarter 2026 earnings. The specific details regarding the new date were not provided in the announcement. This update is part of the company's ongoing communication with its stakeholders.
Read more →InfuSystem to Report Third Quarter 2026 Financial Results on November 3, 2026
InfuSystem Holdings, Inc. will release its third quarter 2026 financial results on November 3, 2026, before market opening. A conference call will follow at 9:00 a.m. Eastern Time to discuss these results. Interested parties can join via phone or a live webcast.
Read more →InfuSystem to Host Investor Webcast on September 24, 2026
InfuSystem Holdings, Inc. will host an investor webcast on September 24, 2026, at 2:00 p.m. ET. The webcast will feature presentations by CEO Carrie Lachance and CFO Barry Steele, discussing the company's corporate strategy and growth initiatives. An interactive Q&A session will follow the presentation, allowing investors to engage directly.
Read more →InfuSystem Announces Financial Results for Second Quarter 2026
InfuSystem has announced its financial results for the second quarter of 2026. The announcement was made from Rochester Hills, Michigan. Further details regarding the financial performance were not provided in the article.
Read more →InfuSystem to Report Second Quarter 2026 Financial Results on August 4, 2026
InfuSystem Holdings, Inc. announced it will release its second quarter 2026 financial results on August 4, 2026, before market opening. A conference call will follow at 9:00 a.m. Eastern Time to discuss these results. The company operates in outpatient care for durable medical equipment, emphasizing its commitment to transparency and investor relations.
Read more →InfuSystem Announces $20 Million Stock Repurchase Program
InfuSystem Holdings, Inc. has announced a new stock repurchase program, allowing for the repurchase of up to $20 million of its outstanding common stock from July 1, 2026, to June 30, 2028. This program supersedes a previous authorization set to expire soon and is intended to enhance shareholder value. CEO Carrie Lachance emphasized the company's confidence in its growth strategy and the strength of its balance sheet, while also maintaining a focus on strategic investments for sustainable growth.
Read more →InfuSystem Announces Financial Results for
InfuSystem Holdings, Inc. reported its financial results for the first quarter of 2026, revealing a net revenue of $33.7 million, marking a 3% decline from the previous year. While there were positive gains in Patient Services and an improvement in adjusted EBITDA margins, the Device Solutions segment experienced a significant 17% decrease in net revenue. The company reaffirmed its full-year guidance and highlighted continued growth potential in the wound care category, alongside the successful implementation of a new ERP system intended to boost operational efficiency.
Read more →InfuSystem to Report First Quarter 2026 Financial Results on May 7, 2026
InfuSystem Holdings, Inc. has announced that it will report its first quarter 2026 financial results on May 7, 2026, before market opens. Following the release, the company will host an investor conference call at 9:00 a.m. Eastern Time to discuss these results. InfuSystem is noted as a prominent provider of healthcare services related to durable medical equipment, supporting outpatient care effectively.
Read more →InfuSystem to Participate at 38th Annual ROTH Conference
InfuSystem Holdings, Inc. will participate in the 38th Annual ROTH Conference on March 23, 2026, at The Ritz-Carlton Laguna Niguel, California. Company executives, including CEO Carrie Lachance and CFO Barry Steele, will host one-on-one meetings for investors. InfuSystem specializes in facilitating outpatient care within the durable medical equipment sector through its Patient Services and Device Solutions platforms, providing comprehensive support for healthcare providers.
Read more →q25investorpr Investor Presentation
InfuSystem's recent investor presentation highlights its ongoing growth and strategic initiatives aimed at enhancing patient care through medical equipment and services. The company has demonstrated a strong financial performance, achieving record revenues for seven consecutive years and an expected adjusted EBITDA of $31.5 million in 2025. InfuSystem's expansion into multiple therapy areas and robust partnerships with leading hospital systems across the U.S. positions it favorably within the healthcare market. The presentation also emphasizes a comprehensive approach to patient support and outcomes, contributing to its successful business model.
Read more →InfuSystem Announces Financial Results for Fourth Quarter and Full Year 2025
InfuSystem Holdings, Inc. reported strong financial results for 2025, marking its seventh consecutive year of record net revenues at $143.4 million, a 6% increase from the previous year. Net income surged by 183% to $6.6 million, and Adjusted EBITDA rose by 24% to $31.5 million. However, the company anticipates a revenue decrease of $7.1 million due to a restructuring of a major biomedical services contract, though it still expects overall revenue growth of 6% to 8% in 2026.
Read more →InfuSystem to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
InfuSystem Holdings, Inc. will announce its preliminary financial results for the fourth quarter and full year 2025 on February 24, 2026. A conference call is scheduled for the same day at 9:00 a.m. ET to discuss these results. The company operates as a healthcare service provider, focusing on outpatient care and durable medical equipment.
Read more →Ambulatory Infusion Pumps used in Pain Management Business by InfuSystem to Receive Separate Payment Under NOPAIN Act Starting January 1, 2026
InfuSystem Holdings, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) will provide separate payment for its electronic infusion pumps under the NOPAIN Act starting January 1, 2026. This decision recognizes the CADD-SolisTM and SapphireTM pumps as effective non-opioid options for pain management. The initiative is intended to promote safer pain management alternatives and reduce reliance on opioids. InfuSystem's CEO expressed optimism about potential growth in their Pain Management business, although concerns remain regarding reimbursement understanding and customer adoption.
Read more →InfuSystem to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025
InfuSystem Holdings, Inc. has announced its participation in the upcoming 16th Annual Craig-Hallum Alpha Select Conference scheduled for November 18, 2025. Key executives, including President Carrie Lachance and CFO Barry Steele, will hold one-on-one meetings with investors. The company provides outpatient care services and operates under a dual platform model, addressing multiple segments of healthcare. However, they face potential risks regarding future growth and economic uncertainties.
Read more →InfuSystem Reports Third Quarter 2025 Financial Results
InfuSystem Holdings, Inc. reported its third quarter 2025 financial results, achieving record net revenues of $36.5 million, a 3% increase from the previous year. The company also noted a 25% rise in net income to $2.3 million. While the Patient Services segment showed significant growth, the Device Solutions segment faced a decline. Management emphasized ongoing improvements and profitable growth strategies, although recent contract restructuring may impact future revenues in biomedical services.
Read more →InfuSystem to Report Third Quarter 2025 Financial Results on November 4, 2025
InfuSystem Holdings, Inc. announced that it will report its third quarter financial results for 2025 on November 4, 2025, prior to market opening. An investor conference call will be held at 9 a.m. Eastern Time the same day, allowing stakeholders to discuss the financial outcomes. The call can be accessed via phone or live webcast. InfuSystem offers services under a two-platform model, focusing on outpatient care across various medical fields.
Read more →InfuSystem to Present at 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025
InfuSystem Holdings, Inc. has announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference scheduled for October 9, 2025. The company's CEO and CFO will represent InfuSystem at the event, highlighting its role as a significant national healthcare service provider. This participation reflects the company's commitment to providing outpatient care and engaging with investors. The conference will occur at the Metropolitan Club in New York City, with opportunities for virtual meetings for interested investors.
Read more →